NCT00411229已完成3 期
A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 1,035
- 试验地点
- 1
- 主要终点
- Recurrence of the original cancer
研究概览
简要总结
Primary:
- To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to observation alone in terms of 3 year disease-free survival (DFS) rate in chemotherapy-naïve patients who underwent potentially curative resection for gastric cancer.
Secondary:
- To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin adjuvant therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ambulatory patients
- •Karnofsky performance status of ≥70 %.
- •Histologically confirmed gastric adenocarcinoma, staged pathologically, stage II (T2N1, T1N2, T3N0), IIIa (T3N1, T2N2, T4N0), and IIIb (T3N2). At least 15 examined lymph nodes are required to ensure the adequate TNM (Tumor Nodes Metastases classification.
- •Patients who underwent curative D2 lymphadenectomy resection for gastric cancer with no macroscopic or microscopic evidence for remaining tumor, who can be randomized to either study arm within 6 weeks after surgery.
排除标准
- •Pregnant or lactating women.
- •Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-child bearing potential.
- •Sexually active males and females (of childbearing potential) unwilling to practice contraception during the study.
- •Any evidence of metastatic disease (including presence of tumor cells in the ascites).
- •Previous cytotoxic chemotherapy, radiotherapy or immunotherapy except corticosteroids, for the currently treated gastric cancer.
- •Major surgery within 4 weeks prior to study treatment start, or lack of complete recovery from the effects of major surgery.
- •History of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix.
- •Clinically significant (i.e. active) cardiac disease e.g. symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication or myocardial infarction within the last 12 months.
- •Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome likely to influence absorption of capecitabine, or inability to take oral medication.
- •Known peripheral neuropathy ≥ CTCAEv3 grade 1 (Common Terminology for Adverse Events). Absence of deep tendon reflexes as the sole neurologic abnormality does not render the patient ineligible.
- •Organ allografts requiring immunosuppressive therapy.
- •Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease.
- •Moderate or severe renal impairment [creatinine clearance equal to or below 50 ml/min (calculated according to Cockroft and Gault)], or serum creatinine > 1.5 x upper limit of normal (ULN).
- •Any of the following laboratory values:
- •Absolute neutrophil count (ANC) < 1.5 x 109/L
- •Platelet count < 100 x 109/L
- •Total bilirubin > 1.5 x ULN
- •ALAT, ASAT > 2.5 x ULN
- •Alkaline phosphatase > 2.5 x ULN.
- •Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without documented dihydropyrimidine dehydrogenase (DPD) deficiency) or patients with known DPD deficiency.
- •Hypersensitivity to platinum compounds or any of the components of the study medications.
- •Received any investigational drug or agent/procedure, i.e. participation in another trial, within 4 weeks before randomization.
- •Blood transfusions or growth factors to aid hematologic recovery within 2 weeks prior to study treatment start.
- •Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or chemically related analogues, such as brivudine.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Active Comparator
Capecitabine + Oxalipatin
干预措施: Capecitabine (Drug)
1
Active Comparator
Capecitabine + Oxalipatin
干预措施: Oxaliplatin (Drug)
结局指标
主要结局
Recurrence of the original cancer
时间窗: From the beginning to end of the study
Development of a new gastric cancer
时间窗: From beginning to end of study
Death due to any cause
时间窗: From the beginning to the end of study
Adverse events
时间窗: From beginning to end of study
Clinical laboratory tests
时间窗: From beginning to end of study
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric CancerGastric CancerNCT02560974Hoffmann-La Roche1,035
Unknown
3 期
Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver MetastasesLiver MetastasesColorectal NeoplasmsNCT00156975Arbeitsgruppe Lebermetastasen und Tumoren384
已完成
3 期
Neoadjuvant Treatment for Advanced Rectal CarcinomaRectal CarcinomaNCT02551237UNICANCER103
Unknown
3 期
Adjuvant Chemotherapy for Biliary Tract Cancer After Curative ResectionGall Bladder CarcinomaCholangiocarcinomaNCT03779035Tianjin Medical University Cancer Institute and Hospital460
招募中
3 期
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node SpreadCervical Cancer TNM Staging Regional Lymph Nodes (N)NCT03534713University Hospital, Toulouse310